Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance
K. Okonechnikov, P. Joshi, V. Koerber, A. Rademacher, M. Bortolomeazzi, J.-P. Mallm, P. B. G. da Silva, B. Statz, M. Sepp, I. Sarropoulos, T. Yamada-Saito, J. Vaillant, A. Wittmann, K. Schramm, M. Blattner-Johnson, , S. M. Pfister
The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.
bioRxiv · Feb 9, 2024Cancer Biology